Merrion to Develop Insulin Drugs with Novo
By Taskin Ahmed
Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)
Published: 24 Nov-2008
DOI: 10.3833/pdr.v2008.i102.106 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novo Nordisk signed an agreement to develop oral insulin analogues using Merrion Pharmaceuticals’ Gastrointestinal Permeation Enhancement Technology (GIPET) in a deal valued at €45 M (US$58 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS